Press releases
- Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
- Amneal to Participate at Upcoming Investor Conference
- Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
- Amneal Reports First Quarter 2024 Financial Results
- Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
- Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
- Amneal to Report First Quarter 2024 Results on May 3, 2024
- Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
- Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
More ▼
Key statistics
As of last trade Amneal Pharmaceuticals Inc (2DT:BER) traded at 6.55, -2.24% below its 52-week high of 6.70, set on Jun 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.55 |
---|---|
High | 6.55 |
Low | 6.55 |
Bid | 6.40 |
Offer | 6.70 |
Previous close | 6.50 |
Average volume | 0.00 |
---|---|
Shares outstanding | 308.65m |
Free float | 120.40m |
P/E (TTM) | -- |
Market cap | 2.17bn USD |
EPS (TTM) | -0.5642 USD |
Data delayed at least 15 minutes, as of Jun 13 2024 16:40 BST.
More ▼